Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in pediatric and young adult sickle cell anemia
NCT02961218Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2017
- Primary completion
- Jun 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of canakinumab in sickle cell anemia (SCA), sponsored by Novartis. Started Apr 2017; status: completed.
02
Drugs
canakinumab
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT02961218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02961218.